Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK)

Sabrina Haroon, Bee‐Choo Tai, Lieng Hsi Ling, Lynette Teo, Andrew Davenport, Leon J. Schurgers, Boon Wee Teo, Priyanka Khatri, Ching Ching Ong, Sanmay Low, Xier Emily Yeo, Jia-Neng Tan, Srinivas Subramanian, Horng‐Ruey Chua, Swee-Yaw Tan, Weng Kin Wong, Titus-Wai-Leong LauMedicine 2020 · DOI

TL;DR

This paper presents the protocol for the Trevasc-HDK clinical trial, investigating whether vitamin K2 supplementation can reduce vascular calcification in patients undergoing hemodialysis. Given the high prevalence of cardiovascular disease and potential vitamin K deficiency in this population, the study aims to provide crucial insights into a safe and inexpensive strategy for mitigating this risk.

What Problem Does This Paper Address?

Patients on long-term hemodialysis face a significantly elevated risk of cardiovascular disease (CVD), with vascular calcification (VC) being a major contributor to mortality and hospitalization. VC in these patients manifests in two forms: intimal calcification (associated with atherosclerosis) and medial calcification (leading to vascular stiffness and increased cardiac workload). While traditional CVD risk factors are present, unique uremic factors like hyperphosphatemia, elevated calcium-phosphate product, and vitamin D supplementation also contribute to VC. A key player in preventing VC is matrix Gla protein (MGP), which requires vitamin K for its functional carboxylation. Sub-clinical vitamin K deficiency is common in hemodialysis patients, leading to reduced functional MGP and thus, increased VC. Current therapies for CVD risk reduction have shown limited success in this population, highlighting the need for novel, safe, and cost-effective interventions. This study addresses the gap in understanding the role of vitamin K2 supplementation in preventing or reducing VC in Asian hemodialysis patients.

Methods

Trevasc-HDK is a single-center, randomized, prospective, and open-label interventional clinical trial. The study will recruit 200 end-stage renal failure patients undergoing maintenance hemodialysis. Participants will be randomized in a 1:1 ratio to either a standard care arm or an active treatment arm. The active treatment arm will receive standard care plus oral vitamin K2 (menaquinone-7, MK-7) at a dose of 360 mcg three times weekly for a total duration of 18 months. Randomization will be stratified by diabetes status.

Key assessments include:

  • Coronary Artery Calcification (CAC) and Aortic Valve Calcification (AVC) scores: Measured using multislice computed tomography (CT) at baseline and 18 months.
  • dp-ucMGP levels: A biomarker for sub-clinical vitamin K deficiency, measured via a chemiluminescent assay.
  • Aortic and Systemic Arterial Stiffness: Assessed using applanation tonometry (SphygmoCorVx) to measure carotid-femoral pulse wave velocity (cfPWV) and aortic augmentation index (AI).

The primary outcome is the absolute difference in CAC score at 18 months between the control and intervention arms. Secondary outcomes include differences in AVC, percentage of patients with CAC regression (≥10%), differences in arterial stiffness, and mortality.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Vitamin K2 as a potential therapeutic target: The study is grounded in the hypothesis that vitamin K2 supplementation can correct sub-clinical vitamin K deficiency, thereby enhancing MGP carboxylation and inhibiting vascular calcification.
  • Focus on Asian population: Previous trials have primarily focused on Caucasian populations. This study aims to provide crucial data for Asian patients, who may have different dietary habits and physiological characteristics.
  • Comprehensive assessment of VC and its consequences: Beyond just calcification scores, the study also measures arterial stiffness and clinical outcomes, providing a holistic view of cardiovascular health.
  • Biomarker-driven approach: The use of dp-ucMGP as a biomarker for vitamin K deficiency allows for a direct assessment of the intervention's impact on vitamin K status.

Key Results

As this is a study protocol, no results are presented. The paper outlines the planned methodology and expected outcomes. The primary outcome is the absolute difference in CAC score at 18 months. Secondary outcomes include absolute difference in AVC, percentage of patients with CAC regression (≥10%), absolute difference in cfPWV and AI, and mortality from any cause within the study period.

Limitations and Future Work

  • Open-label design: While the study is open-label, the primary outcome (CAC score) and secondary outcomes related to imaging and stiffness are assessed by blinded radiologists and technicians, mitigating some bias. However, patient-reported outcomes and adherence might be influenced.
  • Sample size for specific outcomes: While the sample size is powered for the primary outcome, it might be limited for detecting significant differences in some secondary outcomes, particularly mortality.
  • Generalizability: Being a single-center study, the findings might not be directly generalizable to all hemodialysis populations.
  • Future Work: The authors state that evidence of successful regression or retardation of VC will support larger and longer-term trials aimed at reducing CVD mortality and major adverse cardiovascular events. The study also aims to provide local data on VC prevalence and natural history in Asian hemodialysis patients.

Summary updated

Abstract

Evidence of successful regression or retardation of vascular calcification will support the conduct of larger and longer-term trials aimed at reducing cardiovascular disease mortality and major adverse cardiovascular events in this high-risk population using a safe and inexpensive strategy TRIAL REGISTRATION:: ClinicalTrials.gov NCT02870829. Registered on 17 August 2016 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02870829National University Hospital's Institutional Review Board (2015/01000).
BibTeX
@inproceedings{haroon2020treatment,
  author = {Sabrina Haroon and Bee‐Choo Tai and Lieng Hsi Ling and Lynette Teo and Andrew Davenport and Leon J. Schurgers and Boon Wee Teo and Priyanka Khatri and Ching Ching Ong and Sanmay Low and Xier Emily Yeo and Jia-Neng Tan and Srinivas Subramanian and Horng‐Ruey Chua and Swee-Yaw Tan and Weng Kin Wong and Titus-Wai-Leong Lau},
  title = {{Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK)}},
  booktitle = {Medicine},
  year = {2020},
  doi = {10.1097/md.0000000000021906},
}
Figure